Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Aneurysmal Subarachnoid Hemorrhage Treatment Study
The purpose of this study is to investigate the safety and clinical effect of a continuous low-dose intravenous heparin treatment in patients who have an aneurysmal subarachnoid hemorrhage. Nationwide, 88 patients will be recruited for this study. At Rush University, we expect to recruit 8 patients. Treatment will be assigned randomly between low-dose intravenous heparin and prophylactic subcutaneous heparin (standard of care).
In order to participate you must meet the following criteria:
- Are between the ages of 18 and 70 years old.
- Have a ruptured saccular aneurysm confirmed by angiography and repaired by coiling.
- Have GCS 13-15 without focal deficit after repair.
- Have odified Fisher 3 only (minimal IVH allowed).
You will be excluded from the study if any of the following criteria apply to you:
- Have clipping or intracranial stent placement.
- Have anti-platelet or oral anticoagulation prior or during coil (single dose 325mg ASA is OK).
- Have a body weight < 50 or > 150kg.
- Have historical mRS ≥ 2.
This is a partial list of inclusion and exclusion criteria.